Plasma Protease C1-inhibitor Treatment Market: Increasing Incidence of Acute Hereditary Angioedema and Research and Development Activities to Drive the Market Growth


Global Plasma Protease C1-inhibitor Treatment Market size was valued at USD 3.88 Bn in 2022 and is expected to reach USD 14.81 Bn by 2029, at a CAGR of 18.2 %.

Plasma Protease C1-inhibitor Treatment Market Overview

Plasma Protease C1-inhibitor (C1-INH) treatment, also known as C1-INH replacement therapy, is a medical intervention used to manage hereditary angioedema (HAE) and other conditions associated with C1-INH deficiency. By inhibiting enzymes involved in these systems, C1-INH reduces the excessive production of bradykinin, which is responsible for angioedema attacks. It is available in intravenous and subcutaneous formulations, and side effects are generally mild, including injection site reactions and rare hypersensitivity reactions. C1-INH replacement therapy is an effective intervention for managing HAE and can be used for both acute treatment and short-term prophylaxis. The increasing companies’ focus on the development of effective plasma protease C1 inhibitor treatment or drugs treating various health conditions including diabetic macular edema, HAE and others is expected to drive the influence of the market growth.lasma Protease C1-inhibitor Treatment Market

To know about the Research Methodology :- Request Free Sample Report

Plasma Protease C1-inhibitor Treatment Market Drivers and Restrains:

The global plasma protease C1-inhibitor treatment market is expected to show robust growth in the forecast period due to the increasing cases of acute Hereditary Angioedema (HAE) and prophylaxis. The emergence of a few drug variants of C1-inhibitor is considered to be a major breakthrough for patients suffering from HAE. Berinert is a C1-esterase inhibitor for acute HAE that received approval from the European Union in 2011. Haegarda, which is derived from C1-esterase inhibitor is approved in the U.S for routine prophylaxis as a preventive measure against HAE attacks in adolescents and adults. The growing investment for innovation in inhibitor drugs, promising pipeline drugs and novel therapies, and increasing awareness for hereditary angioedema (HAE) are primarily driving the plasma protease C1-inhibitor market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

Plasma Protease C1-inhibitor Treatment Market Segment Analysis:

Based on the drug class, the global plasma protease C1-inhibitor treatment market is segmented into C1-inhibitors, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr). The C1-inhibitors segment is accounted to the dominant share in the market in 2022. The wide usage of this drug class for the treatment of conditions such as prophylaxis and acute hereditary angioedema (HAE) is likely to keep their demand steady across the world. On the other hand, the Kallikrein inhibitor (Kalbitor) segment is expected to register a moderate CAGR of xx% during the forecast period owing to the rising preference for self-administrable drugs. Furthermore, the rising preference for Firazyr is projected to impede the growth of Kalbitor segment. The increasing approval of Kallikrein drugs and positive results obtained for pre-clinical treatment of HAE cases are likely to expand the growth rate of this segment moderately over the upcoming period.Plasma Protease C1-inhibitor Treatment Market

Based on the dosage type, the global plasma protease C1-inhibitor treatment market is segmented into lyophilized and liquid/injectable. The lyophilized segment held the largest market share in 2022 on the back of increasing practice of intravenous administration of drugs for the treatment of HAE. Additional, rising demand for intravenous C1 esterase inhibitor drugs in developing markets of Asia Pacific and Latin America is projected to positively impact the lyophilized segment. However, the liquid/injectable segment is expected to hold significant market share by 2029 due to the rising demand for subcutaneous administration of drugs, less adverse effects, cost effectiveness, and increased preference for Firazyr over Kalbitor by physicians.

Plasma Protease C1-inhibitor Treatment Market Regional Insights:

The global plasma protease C1-inhibitor treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, North America held the largest market share of the plasma protease C1-inhibitor treatment market in 2022. The regional market presents high demand for plasma protease C1-inhibitor treatment owing to the high prevalence of HAE in the U.S. Furthermore, Asia Pacific and Latin America are expected to hold the largest market share of plasma protease C1-inhibitor treatment market during the forecast period. Factors like increasing demand for advanced treatment options, developing economies, and increasing per capita income are anticipated to create growth avenues for the market players in emerging countries over the forecast period.

Plasma Protease C1-inhibitor Treatment Market Competitive landscape

Major Key players operating in this market are Shire plc, Pharming Group N.V., CSL Limited, and Sanquin. Manufacturers in the plasma protease C1-inhibitor treatment are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present comprehensive analysis of global plasma protease C1-inhibitor treatment market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report.

External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global plasma protease C1-inhibitor treatment market dynamics, structure by analyzing the market segments, and project the global plasma protease C1-inhibitor treatment market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the global plasma protease C1-inhibitor treatment market make the report investor’s guide.

Plasma Protease C1-inhibitor Treatment Market Scope: Inquire before buying






Global Plasma Protease C1-inhibitor Treatment Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2021
Market Size in 2022:
US $ 3.88 Bn.




Forecast Period 2022 to 2029 CAGR:
18.2%
Market Size in 2029:
US $ 14.81 Bn.




 Segments Covered:
by Drug Class
• C1-inhibitors
• Kallikrein Inhibitor (Kalbitor)
• Selective Bradykinin B2 Receptor Antagonist (Firazyr)




by Dosage Type
• Liquid/Injectable
• Lyophilized




by Distribution Channel
• Hospital Pharmacies
• Independent Pharmacies and Outlets






Plasma Protease C1-inhibitor Treatment Market, by Region:

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Plasma Protease C1-inhibitor Treatment Market, Key Players:

• Shire plc
• Pharming Group N.V.
• CSL Limited
• Sanquin
• AbbVie
• Alexion
• Argenx
• Bluebird Bio
• Bristol-Myers Squibb/Celgene
• FibroGen
• Gilead
• GlaxoSmithKline
• Novartis
• Vertex
• Takeda Pharmaceutical Company Limited
• Ionis Pharmaceuticals, Inc.
• Pharming Technologies B.V.
• Centogene AG
• BioCryst Pharmaceuticals
• KalVista Pharmaceuticals, Inc
• CSL Behring LLC.
• Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
• Pharming Technologies B.V.
• KalVista Pharmaceuticals, Inc.
• BioCryst Pharmaceuticals

Frequently Asked Questions:

1. Which region has the largest share in Global Plasma Protease C1-inhibitor Treatment Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Plasma Protease C1-inhibitor Treatment Market?
Ans: The Global Plasma Protease C1-inhibitor Treatment Market is growing at a CAGR of 18.2% during forecasting period 2023-2029.

3. What is scope of the Global Plasma Protease C1-inhibitor Treatment market report?
Ans: Global Plasma Protease C1-inhibitor Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Plasma Protease C1-inhibitor Treatment market?
Ans: The important key players in the Global Plasma Protease C1-inhibitor Treatment Market are – Pharming Group N.V., CSL Limited, Sanquin, AbbVie, Alexion, Argenx, Bluebird Bio, Bristol-Myers Squibb/Celgene, FibroGen, Gilead, GlaxoSmithKline, Novartis, Vertex, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., and Centogene AG

5. What is the study period of this market?
Ans: The Global Plasma Protease C1-inhibitor Treatment Market is studied from 2022 to 2029. 




Global Plasma Protease C1-inhibitor Treatment Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Plasma Protease C1-inhibitor Treatment Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Plasma Protease C1-inhibitor Treatment Market Analysis and Forecast
6.1. Global Plasma Protease C1-inhibitor Treatment Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Plasma Protease C1-inhibitor Treatment Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class
7.4. Global Plasma Protease C1-inhibitor Treatment Market Size (US$ Bn) Forecast, by Drug Class
7.5. Global Plasma Protease C1-inhibitor Treatment Market Analysis, by Drug Class
7.6. Global Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis, by Drug Class

8. Global Plasma Protease C1-inhibitor Treatment Market Analysis and Forecast, by Dosage Type
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type
8.4. Global Plasma Protease C1-inhibitor Treatment Market Size (US$ Bn) Forecast, by Dosage Type
8.5. Global Plasma Protease C1-inhibitor Treatment Market Analysis, by Dosage Type
8.6. Global Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis, by Dosage Type

9. Global Plasma Protease C1-inhibitor Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel
9.4. Global Plasma Protease C1-inhibitor Treatment Market Size (US$ Bn) Forecast, by Distribution Channel
9.5. Global Plasma Protease C1-inhibitor Treatment Market Analysis, by Distribution Channel
9.6. Global Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis, by Distribution Channel

10. Global Plasma Protease C1-inhibitor Treatment Market Analysis, by Region
10.1. Global Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Region
10.2. Global Plasma Protease C1-inhibitor Treatment Market Size (US$ Bn) Forecast, by Region
10.3. Global Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis, by Region

11. North America Plasma Protease C1-inhibitor Treatment Market Analysis
11.1. Key Findings
11.2. North America Plasma Protease C1-inhibitor Treatment Market Overview
11.3. North America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class
11.4. North America Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
11.4.1. C1-inhibitors
11.4.2. Kallikrein Inhibitor (Kalbitor)
11.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
11.5. North America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type
11.6. North America Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
11.6.1. Liquid/Injectable
11.6.2. Lyophilized
11.7. North America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel
11.8. North America Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
11.8.1. Hospital Pharmacies
11.8.2. Independent Pharmacies and Outlets
11.9. North America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country
11.10. North America Plasma Protease C1-inhibitor Treatment Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Plasma Protease C1-inhibitor Treatment Market Analysis, by Country
11.12. U.S. Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
11.12.1. C1-inhibitors
11.12.2. Kallikrein Inhibitor (Kalbitor)
11.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
11.13. U.S. Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
11.13.1. Liquid/Injectable
11.13.2. Lyophilized
11.14. U.S. Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
11.14.1. Hospital Pharmacies
11.14.2. Independent Pharmacies and Outlets
11.15. Canada Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
11.15.1. C1-inhibitors
11.15.2. Kallikrein Inhibitor (Kalbitor)
11.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
11.16. Steel Canada Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
11.16.1. Liquid/Injectable
11.16.2. Lyophilized
11.17. Canada Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
11.17.1. Hospital Pharmacies
11.17.2. Independent Pharmacies and Outlets
11.18. North America Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis
11.18.1. By Drug Class
11.18.2. By Dosage Type
11.18.3. By Distribution Channel
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Plasma Protease C1-inhibitor Treatment Market Analysis
12.1. Key Findings
12.2. Europe Plasma Protease C1-inhibitor Treatment Market Overview
12.3. Europe Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class
12.4. Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
12.4.1. C1-inhibitors
12.4.2. Kallikrein Inhibitor (Kalbitor)
12.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
12.5. Europe Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type
12.6. Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
12.6.1. Liquid/Injectable
12.6.2. Lyophilized
12.7. Europe Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel
12.8. Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Independent Pharmacies and Outlets
12.9. Europe Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country
12.10. Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Plasma Protease C1-inhibitor Treatment Market Analysis, by Country
12.12. Germany Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
12.12.1. C1-inhibitors
12.12.2. Kallikrein Inhibitor (Kalbitor)
12.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
12.13. Germany Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
12.13.1. Liquid/Injectable
12.13.2. Lyophilized
12.14. Germany Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
12.14.1. Hospital Pharmacies
12.14.2. Independent Pharmacies and Outlets
12.15. U.K. Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
12.15.1. C1-inhibitors
12.15.2. Kallikrein Inhibitor (Kalbitor)
12.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
12.16. U.K. Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
12.16.1. Liquid/Injectable
12.16.2. Lyophilized
12.17. U.K. Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
12.17.1. Hospital Pharmacies
12.17.2. Independent Pharmacies and Outlets
12.18. France Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
12.18.1. C1-inhibitors
12.18.2. Kallikrein Inhibitor (Kalbitor)
12.18.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
12.19. France Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
12.19.1. Liquid/Injectable
12.19.2. Lyophilized
12.20. France Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
12.20.1. Hospital Pharmacies
12.20.2. Independent Pharmacies and Outlets
12.21. Italy Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
12.21.1. C1-inhibitors
12.21.2. Kallikrein Inhibitor (Kalbitor)
12.21.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
12.22. Italy Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
12.22.1. Liquid/Injectable
12.22.2. Lyophilized
12.23. Italy Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
12.23.1. Hospital Pharmacies
12.23.2. Independent Pharmacies and Outlets
12.24. Spain Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
12.24.1. C1-inhibitors
12.24.2. Kallikrein Inhibitor (Kalbitor)
12.24.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
12.25. Spain Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
12.25.1. Liquid/Injectable
12.25.2. Lyophilized
12.26. Spain Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
12.26.1. Hospital Pharmacies
12.26.2. Independent Pharmacies and Outlets
12.27. Rest of Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
12.27.1. C1-inhibitors
12.27.2. Kallikrein Inhibitor (Kalbitor)
12.27.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
12.28. Rest of Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
12.28.1. Liquid/Injectable
12.28.2. Lyophilized
12.29. Rest Of Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
12.29.1. Hospital Pharmacies
12.29.2. Independent Pharmacies and Outlets
12.30. Europe Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis
12.30.1. By Drug Class
12.30.2. By Dosage Type
12.30.3. By Distribution Channel
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Analysis
13.1. Key Findings
13.2. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Overview
13.3. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class
13.4. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
13.4.1. C1-inhibitors
13.4.2. Kallikrein Inhibitor (Kalbitor)
13.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
13.5. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type
13.6. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
13.6.1. Liquid/Injectable
13.6.2. Lyophilized
13.7. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel
13.8. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Independent Pharmacies and Outlets
13.9. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country
13.10. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Analysis, by Country
13.12. China Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
13.12.1. C1-inhibitors
13.12.2. Kallikrein Inhibitor (Kalbitor)
13.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
13.13. China Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
13.13.1. Liquid/Injectable
13.13.2. Lyophilized
13.14. China Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
13.14.1. Hospital Pharmacies
13.14.2. Independent Pharmacies and Outlets
13.15. India Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
13.15.1. C1-inhibitors
13.15.2. Kallikrein Inhibitor (Kalbitor)
13.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
13.16. India Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
13.16.1. Liquid/Injectable
13.16.2. Lyophilized
13.17. India Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
13.17.1. Hospital Pharmacies
13.17.2. Independent Pharmacies and Outlets
13.18. Japan Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
13.18.1. C1-inhibitors
13.18.2. Kallikrein Inhibitor (Kalbitor)
13.18.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
13.19. Japan Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
13.19.1. Liquid/Injectable
13.19.2. Lyophilized
13.20. Japan Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
13.20.1. Hospital Pharmacies
13.20.2. Independent Pharmacies and Outlets
13.21. ASEAN Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
13.21.1. C1-inhibitors
13.21.2. Kallikrein Inhibitor (Kalbitor)
13.21.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
13.22. ASEAN Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
13.22.1. Liquid/Injectable
13.22.2. Lyophilized
13.23. ASEAN Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
13.23.1. Hospital Pharmacies
13.23.2. Independent Pharmacies and Outlets
13.24. Rest of Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
13.24.1. C1-inhibitors
13.24.2. Kallikrein Inhibitor (Kalbitor)
13.24.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
13.25. Rest of Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
13.25.1. Liquid/Injectable
13.25.2. Lyophilized
13.26. Rest of Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
13.26.1. Hospital Pharmacies
13.26.2. Independent Pharmacies and Outlets
13.27. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis
13.27.1. By Drug Class
13.27.2. By Dosage Type
13.27.3. By Distribution Channel
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Overview
14.3. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class
14.4. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
14.4.1. C1-inhibitors
14.4.2. Kallikrein Inhibitor (Kalbitor)
14.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
14.5. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type
14.6. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
14.6.1. Liquid/Injectable
14.6.2. Lyophilized
14.7. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel
14.8. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
14.8.1. Hospital Pharmacies
14.8.2. Independent Pharmacies and Outlets
14.9. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country
14.10. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Analysis, by Country
14.12. GCC Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
14.12.1. C1-inhibitors
14.12.2. Kallikrein Inhibitor (Kalbitor)
14.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
14.13. GCC Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
14.13.1. Liquid/Injectable
14.13.2. Lyophilized
14.14. GCC Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
14.14.1. Hospital Pharmacies
14.14.2. Independent Pharmacies and Outlets
14.15. South Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
14.15.1. C1-inhibitors
14.15.2. Kallikrein Inhibitor (Kalbitor)
14.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
14.16. South Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
14.16.1. Liquid/Injectable
14.16.2. Lyophilized
14.17. South Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
14.17.1. Hospital Pharmacies
14.17.2. Independent Pharmacies and Outlets
14.18. Rest of Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
14.18.1. C1-inhibitors
14.18.2. Kallikrein Inhibitor (Kalbitor)
14.18.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
14.19. Rest of Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
14.19.1. Liquid/Injectable
14.19.2. Lyophilized
14.20. Rest of Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
14.20.1. Hospital Pharmacies
14.20.2. Independent Pharmacies and Outlets
14.21. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis
14.21.1. By Drug Class
14.21.2. By Dosage Type
14.21.3. By Distribution Channel
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Plasma Protease C1-inhibitor Treatment Market Analysis
15.1. Key Findings
15.2. South America Plasma Protease C1-inhibitor Treatment Market Overview
15.3. South America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class
15.4. South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
15.4.1. C1-inhibitors
15.4.2. Kallikrein Inhibitor (Kalbitor)
15.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
15.5. South America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type
15.6. South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
15.6.1. Liquid/Injectable
15.6.2. Lyophilized
15.7. South America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel
15.8. South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
15.8.1. Hospital Pharmacies
15.8.2. Independent Pharmacies and Outlets
15.9. South America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country
15.10. South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Plasma Protease C1-inhibitor Treatment Market Analysis, by Country
15.12. Brazil Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
15.12.1. C1-inhibitors
15.12.2. Kallikrein Inhibitor (Kalbitor)
15.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
15.13. Brazil Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
15.13.1. Liquid/Injectable
15.13.2. Lyophilized
15.14. Brazil Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
15.14.1. Hospital Pharmacies
15.14.2. Independent Pharmacies and Outlets
15.15. Mexico Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
15.15.1. C1-inhibitors
15.15.2. Kallikrein Inhibitor (Kalbitor)
15.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
15.16. Mexico Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
15.16.1. Liquid/Injectable
15.16.2. Lyophilized
15.17. Mexico Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
15.17.1. Hospital Pharmacies
15.17.2. Independent Pharmacies and Outlets
15.18. Rest of South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class
15.18.1. C1-inhibitors
15.18.2. Kallikrein Inhibitor (Kalbitor)
15.18.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
15.19. Rest of South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type
15.19.1. Liquid/Injectable
15.19.2. Lyophilized
15.20. Rest of South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel
15.20.1. Hospital Pharmacies
15.20.2. Independent Pharmacies and Outlets
15.21. South America Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis
15.21.1. By Drug Class
15.21.2. By Dosage Type
15.21.3. By Distribution Channel
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Shire plc
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Pharming Group N.V.
16.3.3. CSL Limited
16.3.4. Sanquin
16.3.5. AbbVie
16.3.6. Alexion
16.3.7. Argenx
16.3.8. Bluebird Bio
16.3.9. Bristol-Myers Squibb/Celgene
16.3.10. FibroGen
16.3.11. Gilead
16.3.12. GlaxoSmithKline
16.3.13. Novartis
16.3.14. Vertex
16.3.15. Takeda Pharmaceutical Company Limited
16.3.16. Ionis Pharmaceuticals, Inc.
16.3.17. Pharming Technologies B.V.
16.3.18. Centogene AG
16.3.19. BioCryst Pharmaceuticals
16.3.20. KalVista Pharmaceuticals, Inc

17. Primary Key Insights
  • INQUIRE BEFORE BUYING